Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% of pancreatic malignancies, and has median survival of <6 months. There is an urgent need for diagnostic and therapeutic options for PDAC. Centrin1 (CETN1) is a novel member of Cancer/Testis Antigens, with a 25‐fold...

Full description

Bibliographic Details
Main Authors:	Rubin Jiao, Kevin J. H. Allen, Mackenzie E. Malo, Muath Helal, Zewei Jiang, Karishma Smart, Susan V. Buhl, David Rickles, Ruth A. Bryan, Ekaterina Dadachova
Format:	Article
Language:	English
Published:	Wiley 2019-09-01
Series:	Cancer Medicine
Subjects:	177Lutetium 213Bismuth centrin1 pancreatic adenocarcinoma radioimmunotherapy SPECT/CT imaging
Online Access:	https://doi.org/10.1002/cam4.2379

Similar Items

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
by: Kevin J. H. Allen, et al.
Published: (2019-07-01)

Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model
by: Nolwenn eFichou, et al.
Published: (2015-11-01)

Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma
by: Mackenzie E. Malo, et al.
Published: (2020-11-01)

Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
by: Muath Helal, et al.
Published: (2020-02-01)

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
by: Ashleigh Hull, et al.
Published: (2023-08-01)

Combination of anti-retroviral drugs and radioimmunotherapy specifically kills infected cells from HIV infected individuals
by: Dina Tsukrov, et al.
Published: (2016-09-01)

First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study
by: Wolfgang Roll, et al.
Published: (2023-09-01)

Safety Evaluation of an Alpha-Emitter Bismuth-213 Labeled Antibody to (1→3)-β-Glucan in Healthy Dogs as a Prelude for a Trial in Companion Dogs with Invasive Fungal Infections
by: Muath Helal, et al.
Published: (2020-08-01)

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
by: Caroline eBodet-Milin, et al.
Published: (2015-11-01)

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
by: Anna Sundlöv, et al.
Published: (2018-07-01)

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
by: Catherine Meyer, et al.
Published: (2023-12-01)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01)

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
by: Keamogetswe Ramonaheng, et al.
Published: (2024-03-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Centrin diversity and basal body patterning across evolution: new insights from Paramecium
by: Anne Aubusson-Fleury, et al.
Published: (2017-06-01)

Antibody conjugate radioimmunotherapy of superficial bladder cancer
by: Alan Perkins, et al.
Published: (2002-09-01)

K-Ras Binds Calmodulin-Related Centrin1 with Potential Implications for K-Ras Driven Cancer Cell Stemness
by: Ganesh babu Manoharan, et al.
Published: (2023-06-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody
by: Elgström Erika, et al.
Published: (2012-11-01)

Development of 177Lu-phytate Complex for Radiosynovectomy
by: Hassan Yousefnia, et al.
Published: (2013-05-01)

Trypanosoma brucei centrin5 is enriched in the flagellum and interacts with other centrins in a calcium‐dependent manner
by: Fangzhen Shan, et al.
Published: (2019-08-01)

Centrin 2: A Novel Marker of Mature and Neoplastic Human Astrocytes
by: Elisa Degl’Innocenti, et al.
Published: (2022-04-01)

Suaugusiųjų švietimo vaidmuo Rytų ir Centrinės Europos šalyse
by: Danguolė Beresnevičienė
Published: (2016-01-01)

(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
by: Irina Velikyan
Published: (2020-03-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium—177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience
by: Zenaide Silva de Souza, et al.
Published: (2023-09-01)

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
by: Aylin Cankaya, et al.
Published: (2023-05-01)

An assessment tumor targeting ability of 177Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor
by: Eun-Ha Cho, et al.
Published: (2016-07-01)

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
by: William John Yaxley, et al.
Published: (2021-11-01)

Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens
by: Joshua D Nosanchuk, et al.
Published: (2012-01-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

A novel role of centrin in flagellar motility: stabilizing an inner-arm dynein motor in the flagellar axoneme
by: Ziyin Li
Published: (2014-07-01)

The E144 residue of Scherffelia dubia centrin discriminates between the DNA repair protein XPC and the centrosomal protein Sfi1
by: Dora Grecu, et al.
Published: (2014-01-01)

Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer
by: Mei Zhu, et al.
Published: (2023-03-01)

CK2 phosphorylation of human centrins 1 and 2 regulates their binding to the DNA repair protein XPC, the centrosomal protein Sfi1 and the phototransduction protein transducin β
by: Dora Grecu, et al.
Published: (2014-01-01)

Radioimmunotherapy: future prospects from the perspective of brachytherapy
by: Maximilian Fleischmann, et al.
Published: (2021-08-01)

Retrospective Evaluation of The Cases with Malignant Pheochromocytoma: A Single Center Experience
by: Yasemin Aydoğan Ünsal, et al.
Published: (2021-03-01)

Structural Basis for the Functional Diversity of Centrins: A Focus on Calcium Sensing Properties and Target Recognition
by: Marco Pedretti, et al.
Published: (2021-11-01)

Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma
by: Jaline Broqueza, et al.
Published: (2021-05-01)

Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer
by: Jeannette C. Oosterwijk-Wakka, et al.
Published: (2022-10-01)